Replimune Group (NASDAQ:REPL) Hits New 12-Month High – Here’s Why

Replimune Group, Inc. (NASDAQ:REPL) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $12.97 and last traded at $12.54, with a volume of 41626 shares changing hands. The stock had previously closed at $12.44.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Replimune Group from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and set a $17.00 price objective on shares of Replimune Group in a research note on Tuesday. Roth Capital upgraded shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th. Finally, Roth Mkm began coverage on shares of Replimune Group in a research note on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price target for the company. Five analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Replimune Group presently has an average rating of “Buy” and an average price target of $16.80.

Replimune Group Price Performance

The business’s fifty day simple moving average is $11.42 and its 200 day simple moving average is $9.49. The company has a quick ratio of 13.46, a current ratio of 13.46 and a debt-to-equity ratio of 0.16.

Insiders Place Their Bets

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of Replimune Group stock in a transaction on Friday, August 16th. The shares were sold at an average price of $10.18, for a total value of $90,988.84. Following the completion of the transaction, the chief financial officer now owns 101,057 shares of the company’s stock, valued at $1,028,760.26. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. 8.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Replimune Group

Several hedge funds and other institutional investors have recently modified their holdings of REPL. SG Americas Securities LLC acquired a new position in shares of Replimune Group during the first quarter valued at $147,000. Russell Investments Group Ltd. acquired a new position in shares of Replimune Group during the first quarter valued at $140,000. Entropy Technologies LP boosted its holdings in shares of Replimune Group by 18.3% during the first quarter. Entropy Technologies LP now owns 59,326 shares of the company’s stock valued at $485,000 after acquiring an additional 9,180 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Replimune Group by 1.2% during the first quarter. Vanguard Group Inc. now owns 2,770,328 shares of the company’s stock valued at $22,634,000 after acquiring an additional 32,555 shares during the period. Finally, Acadian Asset Management LLC acquired a new position in shares of Replimune Group during the first quarter valued at $927,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.